{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m ulipristal acetate
to a specific field?
Status:
Investigational
Source:
NCT00959881: Phase 1 Interventional Completed Healthy Subjects
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Begacestat (GSI-953 or PF-5212362), a gamma-secretase inhibitor (GSI) that selectively inhibits cleavage of APP over Notch, was discovered for the treatment of Alzheimer's disease. The drug has shown promise results in phase I clinical trials, however further studies were discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03762031: Phase 1 Interventional Completed Healthy
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
M40419 (now GC4419) is a Mn(II)-containing pentaazamacrocyclic selective superoxide dismutase mimetic. It is a first-in-class, small molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen. GC4419 is currently being evaluated in an ongoing randomized Phase 2 clinical trial to assess its effect on the incidence, severity and duration of severe oral mucositis (OM) when given to patients with squamous cell cancers of the head and neck in combination with radiation and chemotherapy. GC4419 has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration.
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
LANPROSTON is an analog of prostaglandin F2 alpha. It is used as veterinary medicament.
Class (Stereo):
CHEMICAL (ACHIRAL)
LAMTIDINE is an irreversible and specific gastric histamine H2-receptor antagonist.
Class (Stereo):
CHEMICAL (ACHIRAL)
Colfenamate is an antypyretic and antiinflammatory compound developed by the German company Tropon, GmbH.
Class (Stereo):
CHEMICAL (MIXED)
Iodetryl is fatty acid derivative patented by Russian company OOO "Nauchno-Proizvodstvennaya Firma "I. M. A." as a colloidal contrast agent.
Status:
Investigational
Source:
NCT00282724: Phase 2/Phase 3 Interventional Completed Ichthyosis, Lamellar
(2006)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid (RA). Liarozole, a retinoic acid (RA) metabolism-blocking agent
(RAMBA) in clinical development, has been granted orphan
drug designation for congenital ichthyosis by the European
Commission and the U.S. Food and Drug Administration. Later, based on the mixed results from a phase II/III trial of liarozole for the treatment of ichthyosis, Barrier decided to discontinue the development of liarozole. Liarozole displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.A large phase III international study was completed
comparing liarozole 300 mg twice daily with cyproterone
acetate (CPA) 100 mg twice daily in a total of 321
patients with metastatic prostate cancer in relapse after
first-line endocrine therapy. The results
indicate that liarozole might be a possible treatment
option for prostate cancer (PCA) following failure of
first-line endocrine therapy.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Rifametane (SPA-S-565) is a semisynthetic derivative of rifamycin (a natural antibiotic produced by Amycolatopsis rifamycinica). It was being evaluated for treatment of bacterial infections. A phase I study showed that administration of rifametane is safe with minor, reversible adverse events such as mild headache, metallic taste and slightly elevated temperature for 3 to 4 hours. Rifametane has anti-tuberculosis activity and was suggested to be a good candidate for phase II clinical trials.
